Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
An affordable HIV-1 drug resistance monitoring method for resource limited settings
Journal of Visualized Experiments, No. 85, Article e51242, Year 2014
Notification
URL copied to clipboard!
Description
HIV-1 drug resistance has the potential to seriously compromise the effectiveness and impact of antiretroviral therapy (ART). As ART programs in sub-Saharan Africa continue to expand, individuals on ART should be closely monitored for the emergence of drug resistance. Surveillance of transmitted drug resistance to track transmission of viral strains already resistant to ART is also critical. Unfortunately, drug resistance testing is still not readily accessible in resource limited settings, because genotyping is expensive and requires sophisticated laboratory and data management infrastructure. An open access genotypic drug resistance monitoring method to manage individuals and assess transmitted drug resistance is described. The method uses free open source software for the interpretation of drug resistance patterns and the generation of individual patient reports. The genotyping protocol has an amplification rate of greater than 95% for plasma samples with a viral load >1,000 HIV-1 RNA copies/ml. The sensitivity decreases significantly for viral loads <1,000 HIV-1 RNA copies/ml. The method described here was validated against a method of HIV-1 drug resistance testing approved by the United States Food and Drug Administration (FDA), the Viroseq genotyping method. Limitations of the method described here include the fact that it is not automated and that it also failed to amplify the circulating recombinant form CRF02_AG from a validation panel of samples, although it amplified subtypes A and B from the same panel. © JoVE 2006-2014. All Rights Reserved.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC4024245/bin/jove-85-51242.mp4
Authors & Co-Authors
Manasa, Justen
South Africa, Durban
College of Health Sciences
Danaviah, Siva
South Africa, Durban
College of Health Sciences
Pillay, Sureshnee
South Africa, Durban
College of Health Sciences
Padayachee, Prevashinee
South Africa, Durban
College of Health Sciences
Mthiyane, Hloniphile R.
South Africa, Durban
College of Health Sciences
Mkhize, Charity
South Africa, Durban
College of Health Sciences
Lessells, Richard John
South Africa, Durban
College of Health Sciences
Seebregts, Christopher John
South Africa, Cape Town
Jembi Health Systems
Rinke de Wit, Tobias Floris
Netherlands, Amsterdam
Universiteit Van Amsterdam
Viljoen, Johannes I.
South Africa, Durban
College of Health Sciences
Katzenstein, David A.
United States, Stanford
Stanford University School of Medicine
De Oliveira, Tulio
South Africa, Durban
College of Health Sciences
Statistics
Citations: 34
Authors: 12
Affiliations: 4
Identifiers
Doi:
10.3791/51242
ISSN:
1940087X
Research Areas
Food Security
Health System And Policy
Infectious Diseases